Dova Pharmaceuticals Inc (NASDAQ:DOVA) major shareholder Life Sciences Maste Perceptive acquired 20,541 shares of the business’s stock in a transaction that occurred on Wednesday, July 3rd. The shares were acquired at an average cost of $14.51 per share, with a total value of $298,049.91. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Life Sciences Maste Perceptive also recently made the following trade(s):
- On Friday, June 28th, Life Sciences Maste Perceptive acquired 427,209 shares of Dova Pharmaceuticals stock. The shares were acquired at an average cost of $13.35 per share, with a total value of $5,703,240.15.
Shares of DOVA opened at $16.11 on Monday. Dova Pharmaceuticals Inc has a 12-month low of $5.62 and a 12-month high of $29.72. The company has a quick ratio of 4.27, a current ratio of 4.46 and a debt-to-equity ratio of 0.20. The company has a market capitalization of $454.83 million, a price-to-earnings ratio of -6.20 and a beta of 2.56. The firm’s 50-day moving average price is $10.47.
Several research firms recently weighed in on DOVA. HC Wainwright boosted their price objective on Dova Pharmaceuticals from $18.00 to $39.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. Wedbush began coverage on Dova Pharmaceuticals in a research report on Wednesday, May 22nd. They set an “outperform” rating and a $19.00 price objective for the company. BidaskClub cut Dova Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, April 10th. Finally, Evercore ISI upgraded Dova Pharmaceuticals from an “in-line” rating to an “outperform” rating and set a $15.00 price target on the stock in a research note on Monday, July 1st. One analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $29.11.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DOVA. PNC Financial Services Group Inc. grew its position in Dova Pharmaceuticals by 14,705.9% during the 4th quarter. PNC Financial Services Group Inc. now owns 5,034 shares of the company’s stock worth $38,000 after acquiring an additional 5,000 shares during the last quarter. Rhumbline Advisers grew its position in Dova Pharmaceuticals by 46.1% during the 4th quarter. Rhumbline Advisers now owns 15,343 shares of the company’s stock worth $116,000 after acquiring an additional 4,843 shares during the last quarter. Two Sigma Investments LP bought a new stake in Dova Pharmaceuticals during the 4th quarter worth approximately $136,000. Squarepoint Ops LLC bought a new stake in Dova Pharmaceuticals during the 4th quarter worth approximately $137,000. Finally, DekaBank Deutsche Girozentrale grew its position in Dova Pharmaceuticals by 22.0% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 13,300 shares of the company’s stock worth $336,000 after acquiring an additional 2,400 shares during the last quarter. Institutional investors and hedge funds own 30.18% of the company’s stock.
Dova Pharmaceuticals Company Profile
Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure.
Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.